Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy

• Status: Completed
• Trial end date: 2010-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Hypertrophic Cardiomyopathy (HCM) is a relatively common inherited heart muscle disease. Many patients experience symptoms of breathlessness, fatigue and chest pain. These symptoms are not always controlled with current therapies.

Recently the investigators showed that a drug called Perhexiline markedly improved exercise capacity and symptoms in patients with heart failure. In this proposal the investigators wish to test whether Perhexiline improves exercise capacity and relieves symptoms in patients with HCM

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Birmingham
• Collaborators: British Heart Foundation; University College London Hospitals; University of Oxford
• Treatments: Perhexiline

Criteria

Inclusion Criteria:

1. Symptomatic Hypertrophic Cardiomyopathy patients

2. Abnormal Peak VO2

3. No significant LVOT obstruction at rest (gradient < 30mmHg)

4. Sinus rhythm

Exclusion Criteria:

1. Abnormal LFT.

2. Concomitant use of amiodarone

3. Pre-existing evidence of peripheral neuropathy.

4. Women of childbearing potential.

5. Patients with ICD's will be excluded from the MR part of the study